Metastatic Colorectal Cancer
Metastatic Colorectal Cancer Market

Metastatic Colorectal Cancer


Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. It is the third leading cause of death from cancer in the United States. 

According to the American Cancer Society, CRC is a cancer that starts in the colon or the rectum; these cancers can also be named colon cancer or rectal cancer, depending on where they start. Also, most CRCs start as a growth on the inner lining of the colon or rectum; these growths are called polyps. 


Metastatic Colorectal Cancer Epidemiology Segmentation in the 7MM


  • Incident Cases of Colorectal Cancer (CRC)
  • Incident Cases of Metastatic Colorectal Cancer (mCRC) 


Metastatic Colorectal Cancer Epidemiological Insights Observed in the 7MM (2021)


  • The total incident cases of Metastatic Colorectal Cancer observed in the 7MM were observed to be 539K in the year 2021
  • The total incident cases of Metastatic Colorectal Cancer observed in the US were observed to be 241K in the year 2021


Metastatic Colorectal Cancer Market Insight


The market size of Metastatic Colorectal Cancer in the 7MM was found to be approximately USD 12,613.9 Million, followed by the US (USD 5,155.1 Million), EU5 (USD 4.618.5 Million), and Japan (USD 2,840.4 million) in the year 2021. 


Metastatic Colorectal Cancer Market Strengths


Recent advances in pathological staging and identification of the mutational status of KRAS (exon2), BRAF (V600E), and PIK3CA have greatly helped in deciding a path for anti-EGFR therapy of mCRC patients.


Metastatic Colorectal Cancer Market Opportunities


The recent inclination toward the development of mutation-specific mCRC therapies has led to the approvals of Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux. This clearly, opens up a window for several upcoming mutation-targeted therapies to enter and capture the market.


Metastatic Colorectal Cancer Emerging Drugs


The emerging drugs in the Metastatic Colorectal Cancer market are

  • Adagrasib (MRTX849) 
  • Cetuximab
  • MK-4280A (favezelimab and pembrolizumab)
  • Lynparza (olaparib)
  • Bevacizumab
  • Elunate (fruquintinib/HMPL-013)
  • Corsela (trilaciclib)
  • Lenvima (lenvatinib/MK-7902/E7080) 
  • Keytruda (pembrolizumab)
  • Modufolin (arfolitixorin)
  • Lumakras (sotorasib) 
  • Vectibix (panitumumab)
  • Masitinib
  • Numidargistat (INCB001158)
  • Enhertu (trastuzumab deruxtecan)
  • Keytruda (pembrolizumab) 
  • ibrutinib
  • Onvansertib
  • RRx-001
  • Lenvima (lenvatinib) 
  • pembrolizumab
  • Tukysa (tucatinib) 
  • Herceptin (trastuzumab)
  • NT-17/GX-I7 (efineptakin Alfa) 
  • Keytruda (pembrolizumab)
  • BDTX-189
  • Magrolimab 
  • Erbitux (cetuximab)
  • ONCOS-102 
  • IMFINZI (durvalumab), and others


Metastatic Colorectal Cancer Key Players 


The key players working in the Metastatic Colorectal Cancer market are


  • Mirati Therapeutics
  • Merck
  • Hutchison Medipharma
  • G1 Therapeutics
  • Eisai
  • Isofol Medical
  • Amgen
  • AB Science
  • Incyte Corporation
  • Daiichi Sankyo
  • AstraZeneca
  • Janssen
  • Cardiff oncology
  • EpicentRx
  • Seagen 
  • Roche
  • NeoImmuneTech (Genexine) 
  • Black Diamond Therapeutics
  • Gilead Sciences 
  • Eli Lilly and Company
  • Ludwig Institute for Cancer Research 
  • Targovax ASA, and others